Stockreport

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease [Read more]